Results 91 to 100 of about 821 (130)

Immunomodulatory functions of glutaminyl cyclases QPCTL and QPCT. [PDF]

Front Immunol
Smid HE, Colotti J, Nölp S, Arlt NS, Weber S, Gumann A, von Hörsten S, Karow A, Schuh W.   +8 more
europepmc   +1 more source

Overexpression of glutaminyl cyclase, the enzyme responsible for pyroglutamate A{beta} formation, induces behavioral deficits, and glutaminyl cyclase knock-out rescues the behavioral phenotype in 5XFAD mice. [PDF]

J Biol Chem, 2011
Jawhar S, Wirths O, Schilling S, Graubner S, Demuth HU, Bayer TA.   +5 more
europepmc   +1 more source

Structural and functional analyses of a glutaminyl cyclase from Ixodes scapularis reveal metal-independent catalysis and inhibitor binding. [PDF]

Acta Crystallogr D Biol Crystallogr, 2014
Huang KF, Hsu HL, Karim S, Wang AH.
europepmc   +1 more source

The isoenzyme of glutaminyl cyclase is an important regulator of monocyte infiltration under inflammatory conditions. [PDF]

EMBO Mol Med, 2011
Cynis H, Hoffmann T, Friedrich D, Kehlen A, Gans K, Kleinschmidt M, Rahfeld JU, Wolf R, Wermann M, Stephan A, Haegele M, Sedlmeier R, Graubner S, Jagla W, Müller A, Eichentopf R, Heiser U, Seifert F, Quax PH, de Vries MR, Hesse I, Trautwein D, Wollert U, Berg S, Freyse EJ, Schilling S, Demuth HU.   +26 more
europepmc   +1 more source

Glutaminyl cyclase knock-out mice exhibit slight hypothyroidism but no hypogonadism: implications for enzyme function and drug development. [PDF]

J Biol Chem, 2011
Schilling S, Kohlmann S, Bäuscher C, Sedlmeier R, Koch B, Eichentopf R, Becker A, Cynis H, Hoffmann T, Berg S, Freyse EJ, von Hörsten S, Rossner S, Graubner S, Demuth HU.   +14 more
europepmc   +1 more source

Structures of human Golgi-resident glutaminyl cyclase and its complexes with inhibitors reveal a large loop movement upon inhibitor binding. [PDF]

J Biol Chem, 2011
Huang KF, Liaw SS, Huang WL, Chia CY, Lo YC, Chen YL, Wang AH.   +6 more
europepmc   +1 more source

Comprehensive medicinal chemistry survey highlights a portfolio of lead molecules for Alzheimer's disease therapy. [PDF]

Front Chem
Bhansali PR, Sonkusare SM, Savale SS, Wijayasinghe YS, Liao Y, Sloan DC, Chaturbhuj GU, Muntean BS.   +7 more
europepmc   +1 more source

The tale of donanemab: God is in the details. [PDF]

J Alzheimers Dis
Saido TC, Iwata N.
europepmc   +1 more source

FTO-mediated m6A modification of QPCT promotes tumorigenesis in lung adenocarcinoma by inducing macrophage chemotaxis and M2 polarization. [PDF]

Am J Cancer Res
Liu B, Yan Y, Guo J, Bu J, Zhang J, Chen L, Zhou F, Ning J, Xu S.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

A patent review of glutaminyl cyclase inhibitors (2004–present)

Expert Opinion on Therapeutic Patents, 2021
Introduction: Glutaminyl cyclase (QC) enzymes catalyze the post-translational processing of several substrates with N-terminal glutamine or glutamate to form pyroglutamate (pE) residue. In addition to physiological functions, emerging evidence demonstrates that human QCs play a part in pathological processes in diverse diseases such as Alzheimer's ...
Judite R M Coimbra, Jorge A R Salvador
exaly   +3 more sources